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Abstract
Introduction Decreased transcription of the BRCA1 gene has
previously been observed to occur in sporadic breast tumours,
making elucidation of the mechanisms regulating the expression
of this gene important for our understanding of the etiology of
the disease.
Methods Transcriptional elements involved in the regulation of
the BRCA1 promoter were analysed by co-transfection
experiments into the human MCF-7 and T-47D breast cancer
cell lines.
Results We have identified a repressor element, referred to as
the UP site, within the proximal BRCA1 promoter whose
inactivation results in increased promoter activity. An E2F
recognition element, previously suggested to mediate
repression via E2F-6, is adjacent to the UP site and its
inactivation also leads to increased BRCA1 expression. These
two elements appear to form a composite repressor element
whose combined effect is additive. The UP element is
composed of two sequences, one of which binds the
ubiquitously expressed ets family transcription factor GABP
alpha/beta. This site is distinct from a previously identified
GABP alpha/beta site, the RIBS element, though the RIBS site
appears to be necessary for derepression of the promoter via
mutations in the UP site. Knockdown of GABP alpha using an
shRNA vector confirms that this protein is important for the
function of both the RIBS and UP sites.
Conclusion The identification of a repressor element in the
BRCA1 promoter brings a new level of complexity to the
regulation of BRCA1 expression. The elements characterized
here may play a normal role in the integration of a variety of
signals, including two different growth related pathways, and it
is possible that loss of the ability to derepress the BRCA1
promoter during critical periods may contribute to breast
transformation.
Introduction
The BRCA1 tumour suppressor gene plays a central role in
the development of breast cancer. In familial cancer, inherit-
ance of a mutant allele leads to tumour formation through the
loss of heterozygosity of this locus [1]. For other identified
tumour suppressor genes, mutations are generally responsible
for both the hereditary and sporadic forms of the same type of
cancer. However, no consistent pattern of mutation of the
BRCA1 gene has ever been identified in sporadic breast can-
cer tumours [2-4]. In contrast, the loss of BRCA1 expression
appears to be an important mechanism driving tumour forma-
tion in sporadic breast cancer cases [5]. There is evidence to
suggest that epigenetic changes and preferential methylation
of sites within the BRCA1 promoter region can lead to this
down-regulation of expression; however, collectively, these
mechanisms are implicated in only a small percentage of spo-
radic tumours [6]. These data suggest that transcriptional reg-
ulation of the BRCA1 gene may play a major role in the loss of
its expression.
As a protein involved in a variety of cellular processes, includ-
ing repair, recombination and transcriptional regulation [7], the
disregulation of BRCA1 activity is expected to have a wide
variety of effects. Artificially increasing the expression of
BRCA1 in tumour cell lines has been shown to decrease
growth and induce apoptosis [5]. Selective inactivation of thePage 1 of 12
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blunted ductal development and tumour formation [8]. Low
BRCA1 levels in human breast cancers are correlated with
tumour progression, increased malignancy and poor progno-
sis [9-11]. This suggests that altered BRCA1 levels have an
ongoing effect on cellular processes.
The transcriptional regulation of BRCA1 expression is com-
plex, being modulated by a variety of hormones, developmen-
tal cues and other effectors (reviewed in [12]). The BRCA1
gene is transcribed divergently with the NBR2 gene, with only
several hundred base-pairs between them [13,14]. A minimal
bidirectional promoter element has been defined and is
located some 200 base-pairs upstream of the BRCA1 tran-
scriptional start site [15]. Within this region we have previously
identified a critical element, referred to as the RIBS site (EcoRI
Band Shift), which interacts with the ets transcription factor
GABP alpha/beta [16]. Functional analysis of the BRCA1 pro-
moter revealed that the RIBS site is important for promoter
activity, and appears to be differentially regulated in the MCF-
7 and T-47D cell lines, with this element being less active in T-
47D cells [16].
GABP alpha/beta is a ubiquitous transcription factor that
binds to GA-rich sequences [17,18]. The human complex
exists as a heterodimer consisting of an ets family helix-loop-
helix DNA-binding domain subunit (GABP alpha), and a
Notch-Ankyrin repeat family subunit (GABP beta) that con-
tains the activation domain as well as a domain required for the
formation of tetrameric complexes. GABP alpha/beta has
been implicated in the regulation of genes in response to cell
growth, activation of respiration related genes [19] and as a
downstream mediator of ErbB3 and ErbB4 signalling [20].
The interaction of the GABP complex subunits with each other
and with numerous other transcription factors and co-activa-
tors defines its ability to regulate target gene transcription.
Here, an element in the BRCA1 proximal promoter, referred to
as the UP (UPstream) site, is identified and characterized. This
site appears to act as a repressor, as mutation of key residues
in this element results in an increase in the transcriptional
activity of the promoter. Mutation of a downstream E2F site
appears to have the same effect on promoter activity. The UP
site is shown to contain a GABP alpha/beta binding element
that is required for repressor activity. Both deletion constructs
and experiments using a small hairpin RNA (shRNA) vector
against the GABP alpha subunit confirm that the RIBS ele-
ment and the GABP complex are required for activation of the
promoter as a result of UP mutations.
Materials and methods
Methylation interference assay
This protocol was modified from Siebenlist and Gilbert [21].
One hundred nanograms of the individual strands of the UP
oligonucleotide (sequence in Figure 1) were labelled using T4
polynucleotide kinase and gamma 32P-ATP. The reaction was
heat inactivated and an excess of cold oligonucleotide was
annealed to the labelled strand. The single-stranded ends
were filled in using Klenow DNA polymerase. The labelled oli-
gonucleotide was purified by exclusion chromatography on a
Sephadex G-50 column in DMS buffer (50 mM Na-cacodylate
pH 8.0, 1 mM EDTA, 50 mM NaCl). Methylation of the labelled
oligonucleotide was carried out in a 200 μl reaction with 2 μg
of poly dIdC and 1 μl of dimethyl sulphate at 37°C for 20 min-
utes. The reaction was terminated with 50 μl DMS stop buffer
(1.5 M NaOAc pH 7.0, 100 μg/ml tRNA, 1.0 M beta-mercap-
toethanol) with 10 μg of poly dIdC also added. The product
was precipitated with ethanol and resuspended in TEN50.
This probe was used in bandshift assays as described and
both DNA:protein and free DNA was isolated from the wet gel
using electroelution. The DNA was precipitated and resus-
pended in 90 μl of water. Piperidine (10 μl) was added and
incubated at 90°C for 30 minutes. Piperidine was removed by
lyophiliszation with several rounds of water addition. The frag-
mented DNA was then eletrophoresed on a 20% urea-poly-
acrylamide gel, dried and autoradiographed.
Cloning
Creation of the L6-pGL2 and L6DR-pGL2 BRCA1 promoter
constructs has been described previously [16]. For these
experiments these promoter constructs were cut with the
restriction enzymes SmaI and HindIII and re-cloned into the
pRL reporter vector (Promega, Madison, WI, USA), which had
been cut with XhoI, blunted using Klenow, and then cut with
HindIII. Creation of the L6-mUP-pGL2 construct was achieved
using nested mutagenic primers and L6-pGL2 as the tem-
plate. The products of these reactions were gel purified,
annealed and a third PCR reaction was then performed to
amplify the full-length mutated L6 promoter. The insert was
cloned into the pGL2 vector using the restriction enzymes
NheI and HindIII, and then re-cloned into the pRL vector as
described above. The L6-mE2F-pRL construct was created in
a similar manner, using nested primers and the L6-pRL con-
struct as the template, and the NheI and HindIII restriction
sites. The L6DR-mUP-pRL and L6DR-mE2F-pRL constructs
were created by cutting the L6-mUP-pRL and L6-mE2F-pRL
constructs, respectively, with the restriction enzymes MscI and
HindIII. The mutant fragments were then cloned into the
L6DR-pRL vector using these same sites. The RIBS multimer
in the GF-TATA-luc vector has been described previously [16].
The UP multimer was cloned upstream of the TATA box in a
similar manner.
The H1 vector primers were derived from [22] and used along
with human genomic DNA to amplify the proximal promoter
from the histone H1 gene. This fragment was cloned into
pBS+ using EcoRI and HindIII. Oligonucleotides correspond-
ing to sequences in GABP alpha and luciferase were synthe-
sized and annealed and the resulting fragments were clonedPage 2 of 12
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All restriction enzymes were obtained from NEB (Pickering,
ON, Canada). Primer sequences are available from the
authors upon request. All constructs were verified by
sequencing.
Production of recombinant proteins
PCR was used to amplify the coding regions of the human
GABP alpha and GABP beta genes, which were the kind gift
of J-I Sawada and H Hanada, using the cDNAs in pCAGGs as
the templates and the primer pairs GABP alpha-(ATG) GGG
TCT AGA ATG ACT AAA AGA GAA GC, GABP alpha-
(TERM) GGG AAG CTT TCA ATT ATC CTT TTC CG and
GABP beta-(ATG) GGG TCT AGA ATG TCC CTG GTA GAT
TTG G, GABP beta-(TERM) GGG GTC GAC GTT CAT TTC
AAT TAA ACA GC, respectively. The products were then
cloned into the pMAL-C2 vector using XbaI/HindIII and XbaI/
SalI, respectively. The recombinant proteins were expressed
and purified according to the manufacturer's protocols. The
purified proteins were eluted with maltose in nuclear dialysis
buffer (25 mM HEPES pH 7.6, 0.1 mM EDTA, 40 mM KCl,
10% glycerol, 1 mM DTT).
Cell culture
The cell lines MCF-7 and T-47D were maintained in RPMI
1640 medium supplemented with 10% fetal bovine serum,
100 units/ml penicillin, and 100 g/ml streptomycin. HeLa cell
lines were maintained in Dulbecco's modified Eagle's medium
supplemented with 10% fetal bovine serum, 100 units/ml pen-
icillin, and 100 μg/ml streptomycin. All lines were obtained
from ATCC (AT CC, Manassas, VA, USA) and maintained at
37°C with 5% CO2.
Transient transfections and luciferase assays
For all transfections for which luciferase activities were meas-
ured, cells were seeded in 12-well plates at a density of 1 ×
105 cells/ml, 24 hours before transfection. All transfections
were carried out using 0.75 μl per well FuGene6 transfection
reagent (Roche Applied Science, Laval, QC, Canada),
according to the manufacturer's instructions. To examine the
relative activity of each promoter, 225 ng of each BRCA1
reporter construct was transfected along with 25 ng CMV-Luc
internal control for a total of 250 ng DNA per well. For the over-
expression studies, each condition consisted of 25 ng CMV-
Luc internal control, 25 ng of each of the GABP expression
vectors or their corresponding empty vector controls, and 175
ng of the specified renilla luciferase reporter vector, for a total
of 250 ng of DNA per well. For the knock-down studies, 50 ng
of the shRNA construct or its empty vector were used in place
of the expression vectors. Each condition was performed in
triplicate. The cells were lysed 48 hours post-transfection
using passive lysis buffer, and assayed using the Dual-Luci-
ferase Assay System (Promega) as per the manufacturer's
instructions. In order to test the effectiveness of the shRNA
constructs, HeLa cells were plated on 12-well plates at a den-
sity of 4 × 104 cells/ml, 24 hours prior to transfection. Trans-
fections were performed using 3 μl of FuGene transfection
reagent and 2 μg of shRNA plasmid, as per the manufacturer's
instructions. Seventy-two hours post-transfection, the cells
were scraped and lysed using 50 μl of modified RIPA buffer
(50 mM Tris-HCL pH 7.4, 1% Igepal C630, 0.25% Na-deoxy-
cholate, 150 mM NaCl, 1 mM EDTA, 1 mM Phenyl-Methyl-Sul-
fonyl-Floride, 1 μg/ml each of aprotinin, leupeptin and
pepstatin, 1 mM Na3VO4, 1 mM NaF) for 15 minutes at 4°C.
An equal amount of 2× SDS-PAGE loading buffer was added
to each lysate.
Western blotting
In order to detect GABP alpha, proteins were resolved by
SDS-PAGE, blotted onto a nitrocellulose membrane and
probed with an antibody directed against human GABP alpha.
Secondary antibody detection was achieved by chemilumines-
cence (Pierce, Rockford, IL, USA). To confirm equal loading,
the blots were then washed with PBS and re-probed with an
Figure 1
Methylation interference assay of the UP sitef t   site. (a) Nuclear proteins were 
used in a bandshift assay with a UP probe that had been chemically 
methylated. The various complexes indicated in (c) were extracted, 
chemically cleaved, individually separated on a denaturing gel and auto-
radiographed. The G residues whose methylation blocks binding to the 
upper and lower complexes are shown in bold in the sequence of the 
UP site. Only the non-coding strand is shown. (b) Location of G resi-
dues sensitive to methylation. Methylation of six G residues, indicated 
by the arrows, block binding to the upper and lower complexes. A UP 
oligonucleotide (UPmut) with mutations at these residues (circled) was 
created. (c) Binding of nuclear proteins to wild-type and mutant UP 
probes. A bandshift assay was preformed with nuclear extracts using 
the wild-type UP oligonucleotide as a probe. The indicated amounts of 
cold wild-type UP or mutant UP oligonucleotides (oligo) were added 
into the reaction. The complexes correspond to Upper, Lower, non-spe-
cific (NS) and unbound (U).Page 3 of 12
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#sc59 Santa Cruz, CA, USA). Secondary antibody detection
was achieved as described above.
Antibodies used for western blotting
Rabbit antibodies were prepared by Chemicon (Temecula,
CA, USA), and were raised against a peptide (ASQEQQM-
NEIC) that corresponds to a region between the pointed and
ets domain of human GABP alpha, which is conserved
between mouse, rat and human sequences. A peptide (MQN-
QINTNPEC) corresponding to a region to the amino-terminal
side of the ankyrin repeats and also conserved between
mouse, rat and human was used to create antibodies against
human GABP beta.
Bandshift reactions
Bandshift conditions used were the same as outlined in [16].
Supershift assays were performed as described in [23], using
the Santa Cruz antibodies GABP alpha (H-2 X), CREB-1 (C-
21) and Ets2 (C-20).
Oligonucleotides
Specific oligonucleotides used are as indicated in the Figures
and the sequences are available on request.
Chromatin immunoprecipitation assays
Chromatin immunoprecipitation (ChIP) assays were carried
out with MCF-7 cells using the ChIP-It Express Enzymatic kit
(Active Motif, Carlsbad, CA, USA) as per the manufacturer's
instructions. Each reaction was performed using chromatin
from 2 × 106 cells and 2 μg of affinity-purified antibody or 5 μl
of whole sera. Affinity-purified antibodies used include: GABP
alpha (Santa-Cruz, (H-180 X)), haemagglutinin (Santa-Cruz,
(Y-11)), and acetylated-histone H3 (Upstate Biotechnology
(Lake Placid, NY, USA). Whole serum antibodies used include
GABP beta (Chemicon) and pre-immune serum (Chemicon).
Results
Identification of the UP binding site in the BRCA1 
proximal promoter
Footprinting analysis of the BRCA1 promoter had identified an
element, referred to here as the UP site, located near the tran-
scriptional start site (data not shown). Bandshift analysis of a
variety of nuclear extracts derived from human breast cancer
cell lines indicated that two slowly migrating complexes were
formed with a UP probe. Self competition experiments con-
firmed that this interaction was specific. In order to further
characterize the interaction between the transcription factor
complexes and the UP site, individual nucleotide contact
points were identified using methylation interference assays
with the UP oligonucleotide (Figure 1a). These results indi-
cated that a series of G residues through the 5' end of the site
were necessary for interaction with the protein complex. To
characterize the specificity of the transcription factor-DNA
complexes formed, gel shift assays were preformed. Mutation
of these nucleotides in the context of a double-stranded oligo-
nucleotide corresponding to the UP site (Figure 1b) eliminates
specific binding of factors to this site (data not shown), while
competition assays with the wild-type or mutant probes con-
firm that the mutant oligonucleotide no longer binds (Figure
1c).
The UP site acts as a repressor
To assess the functional significance of this site for BRCA1
promoter activity, a reporter construct was created with muta-
tions of all six of the nucleotides identified as being critical for
the binding of the complex to the UP site. These mutations
were made in the context of the BRCA1 L6 promoter, which
extends from nucleotide -208 to +27 and which we have pre-
viously determined to have optimal promoter activity in human
breast tumour lines (Figure 2a). This point mutant, referred to
as L6-mUP, was transfected into MCF-7 and T-47D cell lines.
In both cell lines the L6-mUP construct exhibited a three- to
five-fold increase in promoter activity compared to the wild-
type L6 promoter (Figure 2b). This suggests that the UP site
functions as a repressor element in these lines.
The UP and E2F sites form a composite repressor 
element
The presence of an E2F site in the BRCA1 promoter has been
previously reported and was thought to act as an element
mediating E2F-6 repression [24]. This element is immediately
downstream of the UP site (Figures 2a and 3a). Mutation of
the E2F site in the context of the L6 promoter (L6-mE2F)
resulted in increased expression in both the MCF-7 and T-47D
cell lines, with the activity being comparable to that of the L6-
mUP construct (Figure 2b). Mutation of both sites together
produces higher expression than the single mutants, with the
effect being approximately additive (Figure 2b, L6-mUP-
mE2F). These two elements appear to be part of a composite
repressor element where mutation of either site results in loss
of repression of the promoter.
Derepression of a BRCA1 promoter construct is 
dependent upon the RIBS site
We have previously identified a GABP alpha/beta site, which
we refer to as the RIBS element, upstream of the UP site in the
BRCA1 proximal promoter [16]. The RIBS site is required for
optimal promoter activity and is part of the minimal bidirec-
tional transcription element that is involved in the expression of
both the BRCA1 gene and the divergently expressed NBR2
gene [15]. Deletion of this element in the context of the L6 pro-
moter construct decreases its expression significantly and has
a similar effect on the activity of the UP and E2F single-site
mutants in both the MCF-7 and T-47D cell lines (Figure 2b,
L6DR). In MCF-7 cells the construct with both the RIBS dele-
tion and the UP mutation (L6DR-mUP) has comparable activity
to the L6DR mutant, which lacks only the RIBS site. This sug-
gests that the derepression resulting from mutation of the UP
site may be dependent on the function of the RIBS element. APage 4 of 12
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mutant (L6DR-mE2F) and with the triple RIBS, UP and E2F
mutant (L6DR-mUP-mE2F). These results are generally com-
parable in T-47D cells.
Multiple complexes assemble on the UP site
The possible presence of a composite complex with repressor
activity occurring on the UP and E2F sites led us to investigate
the effect of additional mutations in the context of the UPFR6
probe, which includes both the UP and E2F sites (Figure 3b).
A five base-pair region downstream of the original UP muta-
tions was mutated (UPFR6mUS) and when tested in bandshift
assays with nuclear extracts from both MCF-7 and T-47D cells
resulted in the loss of the upper complex (UPPER) seen with
the wild-type probe but retained the lower (LOWER) and non-
specific (NS) complexes (Figure 3c). Similarly, the original UP
mutation (UPFR6mUP) or a two base-pair mutation
(UPFR6mGA) corresponding to the sequence of the middle
UP mutation also resulted in the loss of the upper complex.
The double GA and US mutant (UPFR6mGAmUS) resulted in
loss of binding to the middle complex but appears to produce
an even lower novel complex. These results suggest that the
upper complex is composed of at least two proteins, one bind-
ing to the sequence defined by the GA mutant and another
factor binding to the US region. Disruption of binding of either
of these proteins results in an intermediate complex, and there
is the suggestion that a third protein may bind as the double
mutant still interacts with a faster migrating complex. This fac-
tor could be interacting with the E2F site, although mutation of
this element alone does not result in a change of protein com-
plexes. Given the large size of the upper complex, the effect of
the E2F mutation might not be visible, and may be revealed
only when the other sites are mutated.
GABP alpha/beta binds directly to the UP site
Inspection of the sequence of the UP element reveals several
different potential recognition elements for previously charac-
terized transcription factors. These include two general ets
factor binding sites (GGAA) that are also preferential binding
sites for the ets factor GABP alpha/beta (CGGAA), one on
each of the coding and non-coding strands (Figure 3a,b,
arrows) that correspond to both the GA and US binding sites
for nuclear proteins. GABP alpha/beta sites are often found as
direct repeats, as the protein can form heterotetramers on two
such elements [25], but in the UP site they are inverted
repeats. In order to determine if the UP element, or any other
element in the promoter, could bind GABP alpha/beta, a
series of overlapping double-stranded oligonucleotide band-
shift probes were generated spanning the promoter. This com-
prehensive approach, which we refer to as bandshift scanning,
allows for the specific identification of all binding elements
within the proximal promoter. We then used recombinant
GABP alpha/beta dimers in bandshift assays with these
probes. As expected, a strong complex was seen with the
BRIBS probe as well as with a slightly larger overlapping
probe, FRAG1, as both contain the previously characterized
GABP alpha/beta binding RIBS element [16] (Figure 4a). In
addition, a complex was seen with three other probes, UP,
UPFR6 and UP/PR. The minimal UP element appears to be
sufficient to bind recombinant GABP alpha/beta. The ability of
Figure 2
Analysis of the effect of mutation of the UP site on BRCA1 proximal promoter activity
promoter activity. (a) Schematic representation of the BRCA1 renilla-
luciferase reporter plasmids: mutations were introduced in the context 
of both the full-length proximal promoter (L6-pRL) and a promoter con-
struct from which the RIBS site had been deleted (L6DR-pRL). Point 
mutations were made in the UP site (L6-mUP-pRL, L6DR-mUP-pRL) 
and the downstream E2F binding site (L6-mE2F-pRL, L6DR-mE2F-
pRL), or both sites in combination (L6-mUP-mE2F-pRL, L6DR-mUP-
mE2F). See (b) for sequences. (b) Transfection assays for the effects 
of the various mutants on promoter activity. MCF-7 and T-47D cells 
were cotransfected with 225 ng of one of the BRCA1 promoter con-
structs described above and 25 ng of the internal control vector (CMV-
Luc). Both renilla and firefly luciferase values were measured using a 
dual luciferase assay. The data presented is a representative experi-
ment of mean values of triplicates ± the standard deviation of the rela-
tive light units of the pRL reporter constructs normalized to the 
luciferase activity of the internal control vector. Independent experi-
ments were performed a minimum of three times. Statistical signifi-
cance was determined using a t-test and significant results (p = 0.05) 
are indicated by asterisks and are in relation to the L6 vector.Page 5 of 12
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a supershift assay with an antibody to the GABP alpha subu-
nit. A distinct supershift is seen when nuclear extracts from
MCF-7 (Figure 4b) or T-47D cells (data not shown) were used.
To confirm the in vivo occupancy of the promoter by GABP
alpha/beta, we also carried out ChIP assays using antibodies
directed against GABP and a PCR assay targeted to the
human BRCA1 promoter. MCF-7 chromatin was precipitated
with various controls, including no antibody (Figure 4c, No
Antibody), pre-immune serum from the rabbit used to raise
antibodies against the GABP beta subunit (Figure 4c, Pre-
Immune Serum), and an affinity purified anti-heamagglutinin
tag antibody (Figure 4c, Anti-HA). All of these negative con-
trols gave no or minimal PCR product. A general positive con-
trol using antibodies against acetylated histone H3 (Figure 4c,
Anti-Acetylated H3) gave a robust product as expected. Anti-
bodies against both GABP beta (Figure 4c, Anti-GABPβ) and
GABP alpha (Figure 4c, Anti-GABPα) also gave a positive sig-
nal, confirming the presence of GABP alpha/beta on the
BRCA1 promoter. Due to the lack of spacial resolution inher-
ent in the ChIP assay it is impossible to determine if the
Figure 3
Effects of mutations in the UP site on the binding of endogenous nuclear proteinsi t   sit  on the binding of endogenous nuclear proteins. (a) The sequence of the BRCA1 proximal promoter is shown with 
previously characterized sites boxed. E2F sites characterized by Bindra and Glazer [27] (E2FA and E2FB) are shown by light grey boxes while the 
BRCA1 first exon is shown by the darker box and by the arrow showing the transcriptional start site. The arrows indicate the potential ets/GABP 
binding sites. (b) The sequence of the UPFR6 probe is indicated, which encompasses both the UP and E2F sites (dotted and grey box marked 
E2FB). Arrows identify putative GABP alpha/beta binding sites. The sequences of the various mutant probes are indicated along with their names. 
(c) The 32P-labelled UPFR6 probes described in (b) were incubated in binding reactions with 5 μg of nuclear extract from the MCF-7 and T-47D cell 
lines and bandshift assays were performed. Only the DNA/protein complexes are shown, with the Upper, Lower and non-specific (NS) bands indi-
cated as in Figure 1.Page 6 of 12
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the RIBS, UP or both sites but indicates that it is able to inter-
act with this promoter.
The mutant UPFR6 sites used to characterize the binding of
nuclear proteins to the UP site were also assayed for their abil-
ity to bind recombinant GABP alpha/beta. The UPFR6mUP
probe, which alters the upstream putative GABP element (Fig-
ure 5, UPFR6mUP), as well as a probe containing a two base-
pair mutation of this upstream GABP element alone (Figure 5,
UPFR6mGA) resulted in loss of GABP alpha/beta binding.
Mutation of the downstream putative GABP site (Figure 5,
UPFR6mUS) had no effect on recombinant GABP alpha/beta
binding, while the double mutant (Figure 5, UPFR6mGAmUS)
also resulted in the loss of GABP alpha/beta binding. It thus
appears that the upstream CGGAA sequence in the UP site is
necessary for the binding of GABP alpha/beta, while the
downstream CGGAA sequence is not.
Both the GA and US mutants of the UP site result in 
BRCA1 promoter activation
The GA mutant clearly affects GABP alpha/beta binding and
while the US mutant does not, it does affect the formation of
the upper complex associated with the UP site. Both muta-
tions, alone and in concert, were introduced into the L6
reporter construct and assayed for activity in MCF-7 and T-
47D cells. In MCF-7 cells all three mutant constructs resulted
Figure 4
Binding of recombinant, nuclear extract derived and endogenous GABP alpha/beta to the BRCA1 promoter
GABP alpha/beta to the BRCA1 promoter. (a) A bandshift scanning 
assay of the BRCA1 promoter for GABP complex binding sites was 
preformed using recombinant GABP alpha/beta. Double-stranded DNA 
probes spanning putative protein binding sites were designed for the 
entire length of the BRCA1 proximal promoter and are indicated on the 
schematic (top). Binding reactions were performed with recombinant 
human GABP alpha and beta proteins and each of the 32P-labelled 
probes as indicated by the vertical lines. Samples were run on a 6% 
nondenaturing acrylamide gel and visualized by autoradiography. The 
locations of the free and bound probe are indicated. (b) Supershift 
assays with the UPFR6 probe were performed with 5 μg of MCF-7 
nuclear extract and an antibody directed against CREB, GABP alpha or 
Ets-2. Complexes are as indicated. (c) ChIP assays were preformed 
using chromatin isolated from MCF-7 cells with antibodies against 
acetylated histone H3, GABP beta, GABP alpha and haemagglutinin 
(HA). PCR products obtained using BRCA1-specific primers and the 
immunoprecipitation products are shown.
Figure 5
Effects of mutations in the UP site on the binding of recombinant GABP alpha/beta
GABP alpha/beta. Bandshift reactions were performed with recom-
binant human GABP alpha and beta proteins and 32P-labelled wild-type 
(UPFR6) and mutant UPFR6 site probes, as described in Figure 4a 
with the probes described in Figure 3b. Complexes are as indicated.Page 7 of 12
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construct (Figure 6b). Interestingly, the double GA/US mutant
was less active than either of the single mutants alone. This
may indicate that mutation of either site results in derepression
of the UP element, thereby unmasking the effect of other pro-
teins that then act as activators. Mutation of both sites there-
fore mediates derepression, but also abolishes some of this
additional activation. This suggests then that GABP bound to
the GA site, and some as yet unidentified protein associated
with the US site, can both independently function to activate
the promoter once repression has been lifted. Similar results
were observed in T-47D cells, although the effect of the GA
mutation was much less (Figure 6c). This finding implies that
the factor associated with the US site in MCF-7 cells is absent
or unable to mediate transactivation in this line. As with the UP
and E2F mutants, removal of the RIBS site results in an overall
loss of promoter activity (Figure 6b,c, deleted RIBS (DR)).
shRNA knockdown of GABP alpha/beta inhibits BRCA1 
promoter activity through the RIBS and UP sites
In order to assess the effect of endogenous GABP alpha/beta
levels on BRCA1 promoter activity, an shRNA vector was cre-
ated that targeted the alpha subunit of GABP alpha/beta. This
construct was able to efficiently down-regulate GABP alpha/
beta protein levels by 60% to 80% when transfected into
HeLa cells (Figure 6a) or MCF-7 cells (data not shown). The
activity of the L6 promoter is dramatically reduced by the
cotransfection of the shRNA vector in both MCF-7 and T-47D
cell lines, indicating that GABP alpha/beta is an important
regulator of the BRCA1 promoter in these lines (Figure 6b,c,
+shGABP). The activities of the constructs containing the GA
and US UP site mutations, both of which result in loss of
repression of the promoter, are also greatly decreased by the
GABP alpha shRNA in both the MCF-7 and T-47D lines,
although complete loss of activity is not achieved. This may be
the result of incomplete knock-down of the GABP complex.
Removal of the RIBS site from these constructs, however,
results in further decreases in activity as well as the abrogation
of all mutation-specific activity (Figure 6b,c, deleted RIBS
(DR) +shGABP).
RIBS and UP multimer sites act as GABP alpha/beta-
dependent activator elements
To confirm the activities of the individual GABP alpha/beta
binding sites we cloned multimers of the RIBS and UP sites
upstream of a TATA box-containing minimal promoter [16].
The RIBS multimer was transactivated by cotransfection of the
GABP alpha/beta expression vectors in MCF-7 and T-47D
lines (Figure 7). The shRNA vector dramatically decreased
promoter activity in both cell lines. The UP multimer behaved
in a similar manner to the RIBS multimer reporter, with GABP
alpha/beta cotransfection increasing activity in both lines. The
shRNA vector reduced the activity of the UP multimer in MCF-
7 and T-47D lines but the degree of this decrease was not as
great as for the RIBS element. In isolation, both the RIBS and
Figure 6
Fine mapping the UP site using point mutants. (a) An shRNA vector 
knocks down GABP alpha. HeLa cells were transfected with an empty 
shRNA vector (H1–2) or vectors directed against the luciferase gene 
(shLUC) or the GABP alpha gene (shGABP) and protein lysates col-
lected and analysed by western blot. Control antibodies against Sp1 
(Anti-Sp1) or antibodies recognizing GABP alpha (Anti-GABP) were 
used to detect these proteins. (b,c) The mGA and mUS point muta-
tions alone (L6-mGA, L6-mUS) and in combination (L6-mGAmUS) 
were incorporated into the L6 or L6 with the RIBS site deleted (DR) 
promoters. These were then cotransfected into MCF-7 (b) or T47D (c) 
cell lines with the empty H1–2 vector or with the GABP alpha shRNA 
vector (+shGABP). Cells were harvested 48 hours post-transfection 
and analysed for luciferase activity. The data presented are the mean 
values ± standard deviation of a representative experiment performed 
in triplicate and normalized as described in Figure 2. Statistical signifi-
cance was determined using a t-test and significant results (p = 0.05) 
are indicated by asterisks and are in relation to the L6 or L6DR vector 
in each group.Page 8 of 12
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activator elements in MCF-7 and T-47D cell lines.
Discussion
A composite repressor element is present in the BRCA1 
promoter
The structure and regulation of the BRCA1 promoter has been
of particular interest due to the association of decreased
BRCA1 gene transcription with the development of sporadic
breast cancer [12]. We have identified a new element in the
BRCA1 promoter that functions as a transcriptional repressor.
The sequence of this element is well conserved between
human and mouse promoters (16/18 bases), emphasizing its
importance for regulation of this gene. Inactivation of the UP
element using point mutations results in a three- to five-fold
increase in expression in two different human breast cancer
cell lines. We also determined that a previously identified E2F
binding site [26] immediately downstream of the UP site is
also able to act as a repressor in breast tumour cells. The
repressor element in the BRCA1 promoter appears to extend
from the UP through to the E2F element, though these appear
to have independent functions as mutation of both sites is
additive. The E2F site was originally identified as a potential
mediator of increased BRCA1 expression in response to the
induction of growth, likely mediated through E2F-1 [26]. Sub-
sequently, E2F-6 activity was associated with repression of
the BRCA1 promoter using an shRNA approach and its bind-
ing was thought to occur in a reciprocal manner with E2F-1 to
regulate the promoter [24]. Bindra and Glazer [27] independ-
ently characterized two E2F sites within the proximal BRCA1
promoter, their E2FB site (Figure 3a,b) being coincident with
the previously identified downstream E2F site, and a second
E2F recognition element within the UP site that overlaps with
our GA element. These sites appear to bind both E2F1 and
E2F4 and may be regulated in turn by interaction with p130/
p107. In agreement with our results, mutation of either site
was shown to increase promoter activity; however, the E2FA
site (the UP site) was neither necessary nor sufficient to bind
E2F proteins as judged by DNA capture assays [27]. Overall,
these results emphasize that a composite repressor element
encompasses both the UP and E2F sites, though the question
of the composition and partners of the E2F proteins involved
remains complex.
The role of GABP alpha/beta in promoter regulation
We have previously identified GABP alpha/beta as a critical
regulator of the BRCA1 promoter acting through the RIBS
element [16] and in this paper we have characterized a sec-
ond GABP alpha/beta site within the UP element. The RIBS
element is crucial in that it is required for basal BRCA1 pro-
moter activity as well as being essential for the derepression
of the BRCA1 promoter resulting from mutations in the UP site
(Figure 6, wild-type RIBS verses DR mutants). In contrast to its
interaction with the RIBS element, where it acts solely as an
activator, the binding of GABP alpha/beta to the UP element
appears to also have a repressor function as mutation of the
GABP alpha/beta recognition element leads to loss of UP
mediated repression. However, when the UP site is taken out
of the context of the promoter and multimerised, GABP alpha/
beta was shown to activate this site. This is in keeping with
previous observations that GABP alpha/beta can act as either
an activator or repressor depending on the specific context of
Figure 7
Cotransfection of the GABP alpha/beta expression vectors and the GABP alpha shRNA with RIBS and UP site multimer reporter constructs. MCF-
7 and T-47D cells were transiently transfected with 125 ng of GF-TATA-renilla-luciferase reporter containing oligomerised RIBS or UP sites (RIBSn-
pRL, UPn-pRL), 25 ng of internal control vector (CMV-Luc), and either 25 ng each of GABP alpha and beta expression constructs (light grey bars), 
or 50 ng of their empty control vector (pCAGGs; white bars), or 50 ng of GABP alpha shRNA (black bars) or its empty control vector (H1–2; dark 
grey bars). Cells were harvested 48 hours post-transfection and analysed for luciferase activity. The data presented are the mean values ± standard 
deviation of a representative experiment performed in triplicate and normalized as described in Figure 2. Statistical significance was determined 
using a t-test and significant results (p = 0.05) are indicated by asterisks and are in relation to the empty vector control for each condition (pCAGGS 
or H1–2).Page 9 of 12
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GABP complex is thought to be influenced by the composition
of the heterodimerisation partner of the DNA-binding alpha
subunit. Differential splicing of the GABP beta gene generates
the gamma subunit, which interacts with GABP alpha but
does not allow for tetramerisation [25,29]. The GABP alpha/
gamma subunit is thus thought to function as a repressor, act-
ing in opposition to the GABP alpha/beta complex. We have
not been able, however, to detect the gamma subunit protein
product in these breast cancer cell lines (data not shown),
suggesting this is not the mechanism by which the GABP
complex regulates the activity of the UP site.
Both the GA and US mutants of the UP site result in the loss
of the large molecular weight complex (Figure 3) and induce
similar levels of derepression (Figure 6). This may be due to
cooperative interactions between these proteins in which loss
of either protein results in decreased complex formation and
failure to form a repressor complex (Figure 8). The observation
in MCF-7 cells that the GA/US double mutant promoter con-
struct has lower activity than either of the single mutants (Fig-
ure 6), suggests that once unmasked by loss of the repressor
complex, the factors bound to these sites are individually able
to mediate activation of the BRCA1 promoter. In T-47D cells
the US mutant exhibits an increase in activity similar to what
was seen in the MCF-7 cell line. In contrast, the level of activity
seen with the GA mutant is comparable to that of the GA/US
mutant in this line and both constructs are significantly less
active than in the MCF-7 line. As the complexes obtained by
Electrophoretic Mobility Shift Assay (EMSA) using the various
UP site probes with either MCF-7 or T-47D nuclear extracts
are similar (Figure 3c), it would appear that the factor associ-
ated with the US site in T-47D cells is present on the pro-
moter, but is either inactive or missing a functional co-activator
(Figure 8).
Implications for promoter function
A recent report has identified 53BP1 as a positive regulator of
the BRCA1 promoter that acts through sequences in the UP
element [30]. 53BP1 contains a BRCA1 carboxy-terminal
domain, localizes to sites of double-strand breaks, and acti-
vates the Ataxia Telangiectasia Mutant (ATM) pathway [31]. A
small interfering RNA directed against 53BP1 represses
BRCA1 expression, while an expression vector activates the
promoter. It is suggested that induction of BRCA1 expression
by DNA damage could be mediated by 53BP1. However, a
mutant within the UP site, which abrogates 53BP1 binding
based on bandshift and ChIP assays, still responds to 53BP1
overexpression, suggesting its effect may be indirect. These
results were obtained primarily in U2OS cells, which are a
human osteosarcoma derived cell line, rather than in breast
cells. 53BP1 does not bind to DNA in a sequence specific
manner, suggesting that its effect is likely mediated through its
recruitment by other transcription factors. It is possible that
53BP1 may modulate the repressor and or activator functions
of the UP site during periods of DNA damage to bring about
an increase in BRCA1 levels. However, its role in constitutive
expression of BRCA1 is not clear.
The E2F family is directly involved in mediating cell cycle reg-
ulation and it is known that BRCA1 expression increases in
response to growth [26,32]. Similarly, GABP alpha/beta has
been implicated in the cell cycle regulation of genes such as
Skp2 [33] and indeed appears to regulate a growth mediated
pathway distinct from that of the D-type cyclins [34]. By incor-
porating both of these factors into a composite regulatory ele-
ment, the UP/E2F site may be critical for integrating signals
coming from different growth activated pathways that deter-
mine the nature and level of BRCA1 expression.
The BRCA1 promoter is part of a bidirectional transcription
unit that also directs expression of the NBR2 gene [15]. The
UP element is outside of the minimal bidirectional transcription
unit that is able to direct transcription in both directions. Its
location near the start site for BRCA1 expression may mean
that it plays a role exclusively in regulating BRCA1 expression,
while elements that regulate NBR2/BRCA1 directionality
actually lie farther up and downstream of this region [35].
Figure 8
Model of GABP alpha/beta interaction with the UP site and its effect on BRCA1 promoter activity
BRCA1 promoter activity. Schematic representations of the regulation 
of the BRCA1 promoter. In both MCF-7 and T-47D cells (upper dia-
gram) the RIBS and UP sites, respectively, are shown to bind GABP 
alpha/beta (shaded circles represent the DNA binding alpha subunit, 
with the beta subunit indicated by the dark line) while the E2F site has 
previously been suggested to bind E2F1, E2F4 and E2F6. The UP site 
also binds another unknown protein (oval) and together the UP and 
E2F sites are able to recruit an unknown co-repressor. The GA mutant 
of the UP site (x) disrupts binding of GABP alpha/beta while the US 
mutant affects the binding of the other unidentified factor. In T-47D 
cells this other factor does not appear to be functional (dashed oval). 
See text for explanation.Page 10 of 12
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The identification of a repressor element in the BRCA1 pro-
moter brings a new level of complexity to the regulation of
BRCA1 expression. Given the critical role that decreased
BRCA1 expression has in the development of sporadic breast
cancer, the study of mechanisms that can down-regulate this
key tumour suppressor are of particular importance. The ele-
ments characterized here may play a normal role in the integra-
tion of a variety of signals, including two different growth
related pathways, and it is possible that loss of the ability to
derepress the BRCA1 promoter during critical periods may
contribute to breast transformation.
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